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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers. Its poor prognosis is predominantly due 
to the fact that most patients remain asymptomatic until the disease reaches an advanced stage, alongside the lack of 
early markers and screening strategies. A better understanding of PDAC risk factors is essential for the identification of 
groups at high risk in the population. Genome-wide association studies (GWAS) have been a powerful tool for detecting 
genetic variants associated with complex traits, including pancreatic cancer. By exploiting functional and GWAS data, we 
investigated the associations between polymorphisms affecting gene function in the pancreas (expression quantitative 
trait loci, eQTLs) and PDAC risk. In a two-phase approach, we analysed 13 713 PDAC cases and 43 784 controls and identified 
a genome-wide significant association between the A allele of the rs2035875 polymorphism and increased PDAC risk 
(P = 7.14 × 10−10). This allele is known to be associated with increased expression in the pancreas of the keratin genes KRT8 
and KRT18, whose increased levels have been reported to correlate with various tumour cell characteristics. Additionally, 
the A allele of the rs789744 variant was associated with decreased risk of developing PDAC (P = 3.56 × 10–6). This single 
nucleotide polymorphism is situated in the SRGAP1 gene and the A allele is associated with higher expression of the gene, 
which in turn inactivates the cyclin-dependent protein 42 (CDC42) gene expression, thus decreasing the risk of PDAC. In 
conclusion, we present here a functional-based novel PDAC risk locus and an additional strong candidate supported by 
significant associations and plausible biological mechanisms.
Abbreviations 
CI confidence interval
eQTL expression quantitative trait locus
GWAS genome-wide association study
IRB institutional review board
LD linkage disequilibrium
MAF minor allele frequency
OR odds ratio
PANDoRA PANcreatic Disease ReseArch
PanGenEU European Study Digestive Diseases 
and Genetics
PDAC pancreatic ductal adenocarcinoma
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the seventh most 
common cancer worldwide. It ranks as the fourth cause of 
cancer related deaths in the western world (1,2) and is predicted 
to become the second by 2030 (3).
The incidence varies significantly within regions, contin-
ents, populations and ethnicities (1) suggesting that genetics, 
lifestyle and environmental factors play an important role 
in the development of the pathology. Several epidemiologic 
PDAC risk factors have been identified, including cigarette 
smoking, heavy alcohol intake, type two diabetes mellitus, 
chronic pancreatitis and family history of PDAC (4). Recently, 
Mendelian randomization approaches have identified body 
mass index as a causative risk factor for PDAC (5,6). Moreover, 
rare high-penetrance mutations and high-frequency low-
penetrance variants, discovered through genome-wide 
association studies (GWASs), contribute, alone or in combin-
ation, to the genetic susceptibility of PDAC (7–15). Additional 
susceptibility variants have been identified through large 
multicentric gene candidate approaches and through sec-
ondary analysis of published GWAS data (16–25). The number 
of identified loci is, however, very small if compared with 
breast, prostate or colorectal cancers and the fraction of 
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majority of the cases, the understanding of the underlying 
biological mechanisms and functions of GWAS-identified risk 
loci is still a challenge (26).
In addition, there are no established strategies for early de-
tection and standard screening program for the general popula-
tion (27). The implementation of new strategies to uncover new 
risk factors is of the utmost importance. Defining a complete set 
of PDAC risk factors, both genetic and non-genetic, would be a 
first step in order to perform risk stratification in the population 
and define groups of people at high risk who would then be sub-
jected to more intensive surveillance and/or screening.
In parallel, it would be especially beneficial to identify SNPs 
with an effect on gene function or gene expression regulation 
to gain a deeper insight in the molecular biology of the disease.
In particular, certain germline polymorphisms, called ‘ex-
pression quantitative trait loci’ (eQTLs), are associated with 
gene expression in a wide range of human tissues. Considering 
that many human traits are affected by alterations in gene ex-
pression, eQTLs could represent an effective tool to explore the 
aetiology of human diseases (28–30). The involvement of eQTLs 
in the development of several human diseases, including cancer, 
has been already shown (31–34).
With these premises we hypothesized that pancreatic eQTLs 
are implicated in PDAC development and aimed to find new sus-
ceptibility risk loci. We examined the entire human genome for 
pancreatic eQTLs and analysed their involvement in PDAC sus-
ceptibility in a study on 13 713 PDAC cases and 43 784 controls.
Materials and methods
This study followed a two-phase approach, performing a discovery phase 
leveraging available data from three GWASs for PDAC risk and a validation 
phase for which we used three additional independent populations. In the 
validation phase, we performed de novo genotyping of the most signifi-
cant SNPs, using additional cases and controls recruited by the PANcreatic 
Disease ReseArch (PANDoRA) consortium, and used summary statistics 
of a Japanese GWAS and of  the European Study Digestive Diseases and 
Genetics (PanGenEU).
Study populations
For the discovery phase, data from PanScan I, PanScan II and PanC4 were 
downloaded from the database of Genotypes and Phenotypes (dbGaP) 
web site (study accession numbers: phs000206.v5.p3 and phs000648.v1.p1, 
project reference: #12644). All the individuals were genotyped using ei-
ther Illumina Infinium HumanHap550v3 (PanScan I), Illumina Infinium 
Human610-Quad (PanScan II) or HumanOmniExpressExome-8v1 (PanC4) 
DNA Analysis Genotyping BeadChip. Each participating study collected in-
formed consent from study participants and received approval from the 
responsible institutional review board (IRB) as described in the original pa-
pers (8,9,11). After downloading the genotypes, we performed imputation 
and quality controls. Briefly, the genotypes were phased using SHAPEIT v2 
software (35,36). We discarded SNPs with a minor allele frequency (MAF) 
<0.01, completion rate and call rate <98%, cryptic relatedness (PI_HAT > 
0.2), gender mismatches, low-quality imputation score (INFO score <0.7), 
evidence for violations of Hardy–Weinberg equilibrium (P  <  1  × 10−5), 
leaving 7  509  345 SNPs in the final dataset. Principal component ana-
lysis was performed with PLINK 2.0 (37) including genotypes from all 
populations of the phase 3 of the 1000 Genomes Project. Individuals not 
clustering in the principal component analysis with the 1000 Genomes 
subjects of European descent (N = 439) were excluded from further ana-
lysis. For this phase, genotyping data of 14  269 individuals (7207 cases 
and 7062 controls) were used. The ‘inflation factor’ did not show evidence 
of systematic inflation (λ = 1.000 for PanScan I, λ = 1.015 for PanScan II, 
λ = 1.000 for PanC4 and λ = 1.000 for the aggregate dataset).
As a first replication phase, the summary statistics of a GWAS com-
prising 2039 pancreatic cancer patients and 32 592 controls in the Japanese 
population was used to narrow the list of SNPs under consideration (15).
A total of 6580 individuals (3430 PDAC cases and 3150 controls) from 
the PANDoRA consortium were genotyped to validate the previously 
selected polymorphisms. PANDoRA has been described in detail else-
where (38). It is a multicentric consortium consisting of 11 European coun-
tries (Greece, Italy, Germany, the Netherland, Denmark, Czech Republic, 
Hungary, Poland, Ukraine, Lithuania and UK), Brazil and Japan. PDAC cases 
were defined by an established diagnosis of PDAC and controls were in-
dividuals from the general population without any pancreatic disease at 
recruitment, individuals who were hospitalized for non-tumour related 
causes, or blood donors. Data on sex, age (at diagnosis for cases and at re-
cruitment for controls) and country of origin were collected. Controls were 
recruited in the same geographical regions as the cases. Controls from 
the Netherlands and UK were obtained from the European Prospective 
Investigation into Cancer and Nutrition (EPIC) (39). Only subjects recruited 
in Europe were used for this study. The PANDoRA study protocol was ap-
proved by the Ethics Commission of the Medical Faculty of the University 
of Heidelberg. In accordance with the Declaration of Helsinki, written in-
formed consent was obtained from each participant.
As an additional replication set, we used 1317 cases and 700 con-
trols from the PanGenEU study with genotyped germline DNA. PanGenEU 
has been described in detail elsewhere (40,41). Briefly, this is a case–con-
trol study conducted in Spain, Italy, Sweden, Germany, UK and Ireland, 
between 2009 and 2014. IRB approval and written informed consent 
were obtained from all participating centres and study participants, re-
spectively. DNA samples were genotyped using the Illumina Infinium 
OncoArray-500K. Imputation of missing genotypes was performed using 
IMPUTE2 with 1000 Genomes-phase 3 as reference panel (42).
The final sample size used in this study was therefore 13 713 PDAC 
cases and 43 784 controls as shown in Table 1.
Identification of eQTLs
As a starting point for this work, pancreatic eQTLs were retrieved from 
305 GTEx non-tumour pancreatic samples. The data used for the analyses 
described in this manuscript were obtained from the version V8 GTEx ana-
lysis release (dbGaP Accession phs000424.v8.p2), data access on 6 January 
2021. The initial downloaded raw file contained 1 340 448 million pancre-
atic tissue-specific cis eQTLs, reported with a nominal P < 0.0005 of asso-
ciation with the expression of at least one gene. We excluded variants on 
sex chromosomes and rare variants (MAF < 0.05). After filtering, 576 685 
eQTLs were used in the discovery analysis (PanScan and PanC4). Next, all 
variants showing a discovery P < 1 × 10–4 were analysed in the Japanese 
GWAS dataset. Finally, the polymorphisms showing a P < 0.05 in Japanese 
were analysed in PanGenEU and in PANDoRA. We included in this last step 
all SNPs that were significant in the discovery phase but that were not 
present in the Japanese dataset and excluded all SNPs in known PDAC risk 
loci (±1Mb from a previously reported PDAC risk SNP).
Sample preparation and genotyping
DNA of cases and controls within PANDoRA was extracted from whole 
blood, using the QIamp® 96 DNA QIAcube® HT Kit (Qiagen, Hilden, 
Germany). Genotyping was performed using TaqMan technology 
(ThermoFisher Applied Biosystems, Waltham, MA) in 384-well plates ac-
cording to the manufacturer recommendation. Similar numbers of cases 
and controls were put in each plate. In addition, duplicate samples (8%) 
were added for quality control purposes. Genotypes were called using 
the QuantStudioTM 5 Real-Time PCR system (Thermofisher, USA) and 
QuantStudio software.
Statistical analysis
In the discovery phase, an unconditional logistic regression analysis was 
carried out by computing odds ratio (OR) and 95% confidence interval (95% 
CI) and P-values to test the association between prioritized pancreatic 
eQTLs and PDAC risk. The analysis was performed in 14 269 individuals 
and was adjusted for sex, age and the top eight principal components to 
avoid confounding due to population stratification.
The novel associations were replicated, using an unconditional lo-
gistic regression, in the PANDoRA consortium and in the PanGenEU 
study populations. Additional information on the workflow is given in 
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SNPs genotyped in PANDoRA using the control subjects. Association ana-
lyses were adjusted for sex, age and country of origin (PANDoRA) or five 
principal components (PanGenEU). After the analysis conducted within 
PANDoRA and in PanGenEU, a fixed effect meta-analysis was conducted 
between the results of the two phases.
In order to take into account the number of independent tests, linkage 
disequilibrium (LD), with a threshold of r2 = 0.8, was used to discard SNPs 
representing the same association, leaving a total of 48 456 independent 
variants, setting therefore the Bonferroni-corrected threshold for statis-
tical significance to 0.05/48 456 = 1.03 × 10−6.
Bioinformatics tools
In addition to GTEx, we used two databases to test the regulatory potential 
(i.e. possible changes in transcription factors affinity, regulation of chro-
matin state) of the SNPs showing the best associations: HaploReg v4.1 
(https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php) and 
RegulomeDB (https://www.regulomedb.org/regulome-search/). We used 
LDlink (https://ldlink.nci.nih.gov/) (43–45) to explore the LD between the 
variants we identified and polymorphisms already reported in the litera-
ture. Finally, we used the Roadmap Epigenomics Mapping Consortium 
data (46) and the web-tool 3D-genome interaction viewer (47,48) to 
evaluate the chromatin interaction and the epigenetic annotation in the 
newly identified risk loci.
Ethics statement
Each participating study obtained approval from the responsible IRB and 
IRB certification permitting data sharing in accordance with the NIH Policy 
for sharing of Data Obtained in NIH-Supported or NIH-Conducted Genome 
Wide Association Studies.
The PANDoRA study protocol was approved by the Ethics Commission 
of the Medical Faculty of the University of Heidelberg. In accordance with 
the Declaration of Helsinki, written informed consent was obtained from 
each participant.
Results
In the discovery phase, we analysed 576 685 pancreatic eQTLs 
and observed 36 917 with a statistically significant association 
with PDAC risk, considering a nominal P  <  0.05. LD (with a 
threshold of r2 = 0.8) was then used to discard SNPs representing 
the same locus, leaving a total of 4553 independent variants.
We then filtered for a threshold of significance of P < 10–4, re-
sulting in 48 independent SNPs. A summary of GTEx data on as-
sociations between the 48 SNPs and gene expression or splicing 
(when SNPs act as splicing quantitative traits) in normal pan-
creatic and other tissues is reported in Supplementary Table I.
Among the 48 top SNPs, 34 map to known/putative PDAC 
risk loci. The remaining 14 were analysed in the Japanese 
dataset and one (KRT8-rs2035875) showed a statistically sig-
nificant association (OR  =  1.18, 95% CI 1.09–1.27, P  =  2.18  × 
10−5), 3 (ATP6AP1L-rs2407156, LOC105377095-rs55843545 and 
SRGAP1-rs789744) were not present in the dataset, whereas 
10 did not show a statistically significant association (P < 0.05) 
(Table 2). The first four SNPs were therefore replicated in 
PANDoRA and PanGenEU.
For LOC105377095-rs55843545 a TaqMan probe was not avail-
able and therefore a proxy (LOC105377095-rs12185922, r2 = 0.96 
in 1000G Europeans) was used to genotype PANDoRA cases and 
controls. We did not observe significant deviation from Hardy–
Weinberg equilibrium (P > 0.001) for the four SNPs genotyped in 
PANDoRA. The average call rate was 98% and the concordance 
rate with the duplicate samples was >99%.
Among the four eQTLs that were tested within the PANDoRA 
and PanGenEU populations, we observed an association be-
tween the allele A of KRT8-rs2035875 and an increased risk of 
PDAC in the additive mode of inheritance: OR = 1.08, 95% CI 1.00–
1.17, P = 0.046 in the PANDoRA population and OR = 1.10, 95% CI 
0.95–1.26, P  = 0.21 in the PanGenEU population. The results of 
the meta-analysis of all the studies (PanScan-PanC4, Japanese 
GWAS, PANDoRA and PanGenEU) for KRT8-rs2035875 showed an 
OR = 1.11, 95%CI 1.08–1.15, P = 7.14 × 10−10 and no heterogeneity, 
confirming the association between the A allele and PDAC risk.
Additionally, the A  allele of SRGAP1-rs789744 was associated 
with a decreased risk of PDAC in the additive model of inheritance: 
OR = 0.91, 95% CI 0.83–0.99, P = 0.03 in the PANDoRA population 
and OR = 0.91, 95% CI 0.77–1.08, P = 0.274 in the PanGenEU popula-
tion. The results of the meta-analysis of all the studies (PanScan-
PanC4, PANDoRA and PanGenEU) for SRGAP1-rs789744 showed an 
OR = 0.90, 95% CI 0.86–0.94, P = 3.56 × 10−6 and no heterogeneity, 
confirming an association between the A allele and PDAC risk.
Finally, ATP6AP1L-rs2407156 was significant in PanGenEU 
(OR = 1.23, 95% CI 1.04–1.45, P = 0.018) but not in PANDoRA, and 
the meta-analysis result showed OR  =  1.10, 95% CI 1.05–1.15, 
P = 0.016, and heterogeneity I2 = 52.2%, whereas rs55843545 did 
not show any association in either replication population. The 
results are shown in Table 3.
Functional relevance
The main hypothesis behind the study is the functional effect 
of the SNPs on gene expression in the pancreatic tissue. To ob-
tain this information, we used the GTEx web site that for KRT8-
rs2035875 predicted the A  allele to be associated with higher 
expression of the KRT8 and KRT18 genes and for SRGAP1-rs789744 
Table 1. Description of study populations
PanScan I–II and PanC4 Japanese GWASa PANDoRA PanGenEu Total
Study phase Discovery Replication Replication Replication  
Number of SNPs investigated 576 685 48 4 4  
Number of subjects
 Cases 7207 2039 3150 1317 13 713
 Controls 7062 32 592 3430 700 43 784
 Total 14 269 34 631 6580 2017 57 497
Median age (Q1–Q3)
 Cases 65 (55–75) 62.7|66.3 66 (58–73) 66 (57–73) 65 (55–75)
 Controls 65 (55–75) 43.6|56.3 58 (48–67) 65 (55–75) 65 (55–75)
Sex
 Female 47% 33.6%|61.0% 45% 42% 45%
 Male 53% 39.0%|66.4% 55% 58% 55%
aNumbers obtained from the study of Lin et al. 2020 performed on the Asian population (61), this study is a meta-analysis of three populations, we reported informa-
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Table 2. List of SNPs associated with PDAC risk in PanScan I–II and PanC4 and their replication in the Japanese GWAS






rs3827749 1:230841559 A G 18 [O] AGT rs1326889; Walsh N, 2018 7.34E-05 0.60
rs5051 1:230849872 T C 42 [O] AGT rs1326889; Walsh N, 2018 7.66E-05 0.80
rs4908325 1:99989064 T A 30 [O] LINC01708  4.36E-05 0.75
rs148608463 12:121413027 A G 37 [O] HNF1A-AS1 rs1182933; Klein, 2018 8.69E-06 0.06
rs11065385 12:121423386 A G 33 [O] HNF1A rs7310409; Childs, 2015 5.04E-06 0.12
rs2035875 12:53295917 A G 50 [O] KRT8  3.41E-05 2.18E-05
rs789744 12:64485360 A G 25 [O] SRGAP1  7.09E-05 NA
rs11618832 13:28477111 A G 43 [O] PLUT rs9554197; Childs, 2015 4.11E-08 1.66E-05
rs7994281 13:28534916 G C 27 [N] CDX2 rs9554197; Childs, 2015 4.59E-05 6.48E-04
rs7146643 14:105757392 C T 31 [O] BRF1  8.53E-05 0.99
rs11248878 16:1511758 G A 13 [O] CLCN7  4.53E-05 0.90
rs8054218 16:75252161 G A 12 [N] CTRB1 rs7190458; Wolpin, 2014 2.07E-06 0.59
rs1035539 16:75276775 G A 35 [O] BCAR1 rs7190458; Wolpin, 2014 7.98E-06 0.48
rs8046743 16:75294122 A T 45 [O] BCAR1 rs7190458; Wolpin, 2014 1.99E-05 0.96
rs10871308 16:75342846 C T 24 [O] CFDP1 rs7190458; Wolpin, 2014 2.17E-05 0.63
rs37596 16:75498320 A C 19 [N] CFDP1 rs7190458; Wolpin, 2014 3.91E-06 0.58
rs2325748 17:45974251 T C 30 [O] SP2  6.28E-05 0.48
rs12601827 17:46016613 G A 44 [O] SP2-AS1  9.98E-05 0.72
rs2236141 22:29137870 T C 14 [O] CHEK2 rs16986825; Wolpin, 2014 3.26E-05 0.02
rs5762799 22:29187380 T G 19 [N] XBP1 rs16986825; Wolpin, 2014 2.34E-05 0.01
rs5762829 22:29228130 C T 17 [O] ZNRF3 rs16986825; Wolpin, 2014 1.04E-05 7.40E-04
rs13058460 22:29258509 G C 22 [O] ZNRF3 rs16986825; Wolpin, 2014 1.60E-05 1.73E-03
rs5762870 22:29261159 T C 31 [O] ZNRF3 rs16986825; Wolpin, 2014 6.59E-05 1.77E-05
rs5762879 22:29286180 T C 19 [O] ZNRF3 rs16986825; Wolpin, 2014 1.21E-05 1.38E-03
rs16986825 22:29300306 T C 16 [O] ZNRF3 rs16986825; Wolpin, 2014 5.95E-05 0.01
rs55843545 3:54035492 A G 29 [O] LOC105377095  4.73E-05 NA
rs2407156 5:81636368 G A 25 [O] ATP6AP1L  9.45E-05 NA
rs2343590 6:166759622 C G 26 [O] LOC100289495  3.53E-05 0.68
rs1122553 6:33798524 A C 18 [N] MLN  8.14E-05 0.54
rs6905353 6:33813043 G T 31 [N] LINC01016  5.02E-05 0.22
rs6462989 7:40869754 C A 33 [O] SUGCT rs17688601; Childs, 2015 6.00E-05 0.03
rs1733483 7:40873221 A G 50 [O] SUGCT rs17688601; Childs, 2015 4.71E-05 0.02
rs12701838 7:40877473 G A 26 [O] SUGCT rs17688601; Childs, 2015 3.26E-09 0.75
rs2410517 8:17151259 C G 39 [O] VPS37A  1.64E-05 0.83
rs6985312 8:17168304 G C 34 [O] MTMR7  9.58E-05 0.75
rs2943547 8:76451098 A G 46 [O] HNF4G rs2941471; Klein, 2018 1.87E-05 0.83
rs2941469 8:76469031 T C 42 [O] HNF4G rs2941471; Klein, 2018 1.01E-06 0.62
rs7855466 9:136121303 T C 16 [N] ABO rs505922; Amundadottir, 
2009
5.66E-05 2.38E-07
rs8176715 9:136133148 T C 41 [O] ABO rs687289; Wolpin, 2014 1.75E-05 1.10E-03
rs512770 9:136133506 A G 20 [O] ABO rs687289; Wolpin, 2014 2.53E-05 0.12
rs8176645 9:136149098 A T 39 [O] ABO rs505922; Amundadottir, 
2009
8.60E-15 3.81E-05
rs616154 9:136150466 C T 45 [O] ABO rs505922; Amundadottir, 
2009
9.27E-12 0.59
rs8176632 9:136152547 T C 16 [N] ABO rs687289; Wolpin, 2014 9.96E-05 0.80
rs633862 9:136155444 C T 43 [N] ABO rs505922; Amundadottir, 
2009
3.96E-06 0.02
rs9650778 9:136184798 T C 13 [O] LCN1P2 rs687289; Wolpin, 2014 2.42E-05 0.56
rs11789139 9:136185324 G C 18 [N] LCN1P2 rs505922; Amundadottir, 
2009
2.66E-06 0.65
rs567493 9:136185528 A G 26 [N] LCN1P2 rs687289; Wolpin, 2014 9.80E-05 1.93E-03
rs4962153 9:136323754 A G 15 [O] ADAMTS13 rs687289; Wolpin, 2014 5.31E-06 0.53
SNP, rs-ID; POS, chromosome and variant position Genome Reference Consortium Human Build 37 (GRCh37); m, minor allele; M, major allele; MAF, minor allele fre-
quency in PanScan I, II and PanC4 data; Gene: [O] ‘overlapped’ if the SNP is located inside the gene region, [N] the ‘nearest’ gene; NES, normalized effect size of SNPs 
on gene expression level in the pancreatic tissue samples from GTEx. NES > 0 indicates that the minor allele of the SNP is associated with increased expression of 
the gene, NES < 0 indicates association with decreased expression; eQTL, gene whose expression level is associated with SNP in the pancreatic tissue samples from 
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predicted the A allele to be associated with higher expression of 
the SRGAP1 gene.
The KRT8-rs2035875 SNP is located in a regulatory region and 
enhancer for the KTR8 and KRT18 genes in pancreatic tissue. 
The tool 3D-Genome Interaction Viewer and database showed 
that the KRT8-rs2035875 SNP interacts with the KTR8 and KRT18 
genes and suggested also a long-range interaction with the 
NR4A1 locus that is located 880 000 bp away.
RegulomeDB gave for SRGAP1-rs789744 a score of 0.18 and 
a rank of 7, indicating a very low functional potential, whereas 
HaploReg confirmed the SNP as a multi-tissue eQTL. The mod-
erate potential functionality of the locus SRGAP1-rs789744 was 
confirmed also by roadmap epigenomics consortium data that 
report a weak transcription functionality and no epigenetic 
function.
Discussion
PDAC is a polygenic and complex multifactorial disease for 
which aetiology remains still not completely understood. At pre-
sent, there are no molecular signatures to detect PDAC at early 
stages and genetic susceptibility has been less studied com-
pared with other more common cancers. Nonetheless, several 
risk SNPs have been identified and, as for several other cancer 
types, many are not in gene coding regions. Instead, they are 
situated in intergenic and intronic regions and probably are in-
volved in gene expression regulation. SNPs involved in regu-
lating gene expression are called eQTLs and assessing their 
association with PDAC risk will not only further increase our 
knowledge on the genetic susceptibility but also shed light on 
their possible role in the etiopathogenesis of the disease and 
in the biological mechanisms involved in it. With these prem-
ises, we combined a GWAS approach and a genome-wide in-
vestigation of pancreatic eQTLs. We used a two-phase strategy. 
In the discovery phase, we analysed 14 269 individuals and we 
identified 48 eQTLs associated with PDAC risk (P < 10–4). Checking 
and filtering for possible association and proximity with loci dis-
covered in previous studies, we obtained a list of four novel vari-
ants to be tested in a validation phase and a list of 34 SNPs in 
loci already identified as PDAC risk regions.
Among the latter, a group of 11 SNPs are located on chromo-
some 9 in proximity of the ABO locus. Most are in moderate to 
high LD with rs505922, the index SNP that was identified in the 
first GWAS on PDAC risk (8). They are reported by GTEx to be 
strong eQTLs for ABO itself, as well as for nearby genes SURF1 
and SURF6. Although the functional link between ABO and PDAC 
risk is still unclear, it is worth noting that expression level of ABO 
was reported to be associated with PDAC risk in transcriptome-
wide association studies (49,50). To the best of our knowledge, no 
relation between SURF1 or SURF6 and PDAC has been reported.
Additionally, rs8054218, rs1035539, rs8046743, rs1087 
1308 and rs37596 are located in the region of the BCAR1/ 
CTRB1/CTRB2 locus on chromosome 16 (10), although they 
are in low LD (r2  =  0.07) with rs7190458, the top SNP at the 
locus. These SNPs are strong eQTLs and splicing QTLs for a 
number of genes in multiple tissues, including the pancreas. 
Among the genes whose expression is associated with the 
eQTLs on chromosome 16, there are CTRB1 and CTRB2 (51), 
two chymotripsinogens that are precursors of pancreatic pro-
teolytic enzymes. Genetic variation at this locus is associated 
also with susceptibility to chronic pancreatitis (52), which is a 
strong risk factor for PDAC.
The observation that some of the SNPs identified with this 
approach are located in established PDAC risk loci represents an 
implicit validation of this strategy. Additionally, it provides hints 
to the possible function of loci that were identified previously in 
the context of epidemiological studies but lacking mechanistic 
explanation of their role in disease susceptibility.
From a statistical point of view, the strongest association 
we observed was between the A  allele of KRT8-rs2035875 SNP 


















A/G MAF  
OR (95% CI)  
P-value
0.29  
0.90 (0.85–0.94)  
4.73 × 10−5
NA 0.28  
1.01 (0.92–1.10)  
0.89
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NA 0.25  
1.03 (0.94–1.12)  
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P-value
0.25  
0.90 (0.85–0.95)  
7.09 × 10−5
NA 0.23  
0.91 (0.83–0.99)  
0.03
0.25  










G/A MAF  
OR (95% CI)  
P-value
0.50  
1.10 (1.05–1.16)  
3.41 × 10−5
0.39  
1.18 (1.09–1.27)  
2.18 × 10−5
0.49  
1.08 (1.00–1.17)  
0.05
0.48  






aMajor and minor allele.
bMAF, minor allele frequency; OR, allelic odds ratio and corresponding 95% confidence interval; P-value results.
cNumber of cases and controls (cases|controls).
dFor this SNP, a genotyping assay was not available at the time of genotyping within PANDoRA. A SNP in strong LD, having TaqMan assays available, was chosen in-
stead (rs12185922 proxy of rs55843545).
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on chromosome 12 and increased risk of developing PDAC 
(P = 7.14 × 10−10 in the overall meta-analysis). According to GTEx, 
the A allele is associated with increased expression of the keratin 
8 and 18 (KRT8 and KRT18) genes in the pancreatic tissue. The 
role of KRT8-rs2035875 in regulating the KRT8 and KRT18 genes 
is also supported by the Epigenomics Mapping Consortium data, 
where this SNP is annotated as super-enhancer of these genes. 
Furthermore, the 3D-Genome Interaction Viewer tool confirmed 
the interaction of the KRT8-rs2035875 locus with the genomic 
regions where KRT8 and KRT18 are located. Keratins K8 and K18 
are the major components of the intermediate-filament cyto-
skeleton of simple epithelia. Increased levels of these keratins 
have been correlated with various tumour cell characteristics, 
including progression to malignancy (53–55), invasive behaviour 
and drug sensitivity, although their exact role in tumorigenesis 
has not yet been clarified.
In an experiment conducted using transgenic mice ex-
pressing the human KRT8 gene, the role of this gene in pancreatic 
tissue development and health was highlighted, particularly on 
the exocrine component of the pancreatic tissue (55). In detail, 
the study showed that the amount of K8/K18 transcript was es-
timated to be ~3-fold higher in transgenic mice with anomalous 
pancreas than in non-transgenic or normal-pancreas transgenic 
mice. We observed that the A allele of KRT8-rs2035875 was as-
sociated with increased expression of KRT8 and KRT18 in pan-
creatic tissue, and the same allele is associated with increased 
risk of developing PDAC, suggesting a role of the KRT8 and KRT18 
overexpression in pancreatic cancer.
The association of  the KRT8 gene considering a gene asso-
ciation approach (all the SNPs in the region together) was also 
shown by Lin et al. (15), however, the association between KRT8-
rs2035875 and PDAC risk was not reported.
In the meta-analysis, the A  allele of the Slit-Robo GTPase-
Activating Protein 1 (SRGAP1)-rs789744 showed an association 
with decreased risk of developing PDAC; however, this associ-
ation does not reach the Bonferroni threshold (1.03 × 10–6) but it 
is very close (3.56 × 10−6).
The decrease in risk associated with the A allele may have 
a biological explanation. According to GTEx, the A  allele is 
associated with increased expression of the SRGAP1 gene in 
the pancreatic tissue. The protein encoded by SRGAP1s gene 
is a GTPase activator that interacts with ROBO1 and CDC42 
to negatively regulate various processes such as cell cycle 
progression, cell morphology, endocytosis cell adhesion and 
migration (56,57). ROBO1 and ROBO2 gene expression and regu-
lation is key in pancreatic cancer, as reported by Pinho et  al. 
(58), and therefore an eQTL that changes the expression of 
the SRGAP1 in the pancreas could have an impact on the dis-
ease aetiology. Moreover, in a recent review, Xiao et al. reported 
that CDC42 abnormal expression could be involved in various 
human tumours such as lung, breast, kidney, gastric, prostate, 
thyroid and PDAC, promoting neoplastic growth and metas-
tasis (57). In addition, Feng et  al. reported that SRGAP1 plays 
a role in colorectal cancer, in particular its downregulation is 
associated with tumour progression and poor prognosis due 
to the diminished inhibition of CDC42 (59). Moreover, He et al. 
reported that three genetic variants (rs781626187, rs797044990 
and rs114817817) are associated with decreased SRGAP1 pro-
tein level and are associated with increased risk of developing 
papillary thyroid cancer (60). Two of the SNPs (rs114817817 and 
rs789744) share a modest degree of LD (D′ = 1, r2 = 0.0011 in the 
European population of the 1000 genomes database) and are 
close to each other (17 387 bp) and therefore could represent 
the same locus. There are no data in LDlink for the remaining 
two SNPs (rs781626187, rs797044990). The overall picture 
that could be gathered from these data is that the A allele of 
SRGAP1-rs789744 upregulates the expression of SRGAP1 that, 
in turn, increases the inhibition exerted by SRGAP1 on CDC42 
that could decrease the risk of developing PDAC. As suggested 
by He et al. for thyroid cancer, the locus around SRGAP1 could 
be a low-penetrance modifying gene also for PDAC develop-
ment. However, the locus where rs789744 is located is reported 
by the Roadmap Epigenomics Mapping Consortium data as a 
region with quiescent regulatory status and low and weak en-
hancer transcription role.
Clear strengths of this study are represented by the very large 
sample size and the two-phase approach that may decrease the 
chance of reporting spurious finding.
Possible limitations of this work are that we excluded rare 
variants and that we used a population of East Asian descent 
as a first validation step. However, considering that the success 
rate in validating SNPs across populations is limited, our choice 
has the advantage of identifying (when present in both datasets) 
risk loci for both ethnicities. We performed only individual eQTL 
analyses and did not combine them into gene-level predictions, 
because pancreatic cancer transcriptome-wide association 
studies have already been published, using the same PanScan 
I–II and PanC4 data we used (49,50).
In conclusion, we present here a potentially interesting as-
sociation of two functional SNPs supported by a plausible bio-
logical mechanism influencing PDAC risk. The emergence of 
eQTLs as cancer risk markers highlights the importance of 
using functional SNPs to generate new insights into the under-
standing of the genetic basis of complex human traits.
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